(PTGX) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily discusses Protagonist Therapeutics Inc. (NASDAQ: PTGX), highlighting divergent sentiment across all horizons suggesting choppy conditions. It identifies a 35.6:1 risk-reward short setup and provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal analysis with support and resistance levels for near-term, mid-term, and long-term horizons.
After exercising options, Protagonist Therapeutics (PTGX) CFO sells 58,629 shares under a trading plan.
Protagonist Therapeutics (PTGX) CFO Asif Ali exercised options for 58,629 common shares on September 30, 2026, at various prices ranging from $12.17 to $38.98 per share. Concurrently, he sold all 58,629 shares in two transactions at weighted-average prices of $141.77 and $141.78 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2026. This insider trading activity resulted in an approximate pre-tax spread of $6.92 million.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts
Protagonist Therapeutics (NASDAQ:PTGX) has received a "Moderate Buy" consensus rating from eighteen brokerages, with an average 12-month price target of $147.13. The company recently reported strong financial results, exceeding EPS and revenue expectations with a 3,746.8% year-over-year revenue increase. Institutional investors hold a substantial 98.63% of PTGX shares, reflecting significant confidence in the company.
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 58,629 Shares of Company Stock
Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali sold 58,629 shares of company stock for approximately $8.31 million on September 30th, reducing his holdings by nearly 50%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Protagonist Therapeutics has shown strong financial performance with significant revenue growth and a "Moderate Buy" consensus rating from analysts.
Form 144 PROTAGONIST THERAPEUTICS For: 1 October By Investing.com
This article announces the filing of Form 144 for Protagonist Therapeutics (PTGX) on October 1st. Form 144 indicates the intent to sell restricted securities. The brief notice highlights this financial disclosure for the company.
Form 144 PROTAGONIST THERAPEUTICS For: 1 October By Investing.com
The article announces the filing of Form 144 for Protagonist Therapeutics (PTGX) on October 1st, 2026. Form 144 is a notice of the intent to sell restricted securities, often filed by company insiders. The brief news item also notes a slight dip in PTGX stock at the time of publication.
Officer Asif Ali plans to sell 58,629 Protagonist Therapeutics (PTGX) shares.
Protagonist Therapeutics officer Asif Ali has reported an intended sale of 58,629 common shares, valued at approximately $8.26 million. The shares were acquired through the exercise of stock options, and the proposed sale date is September 30, 2026. Morgan Stanley Smith Barney LLC is listed as the broker for this Rule 144 transaction.
Form 144 | Protagonist Therapeutics(PTGX.US) Officer Proposes to Sell 8.26 Million in Common Stocks
Protagonist Therapeutics (PTGX.US) officer ASIF ALI has filed a Form 144, indicating an intention to sell 58,629 shares of common stock, valued at approximately $8.26 million. This filing, made on September 30, adheres to SEC Rule 144, which requires individuals like executive officers to report proposed sales exceeding specific thresholds. The article explains Form 144 as a notice of proposed securities sale for US-listed company insiders.
Possible Bearish Signals With Protagonist Therapeutics Insiders Disposing Stock
The article suggests potential bearish signals for Protagonist Therapeutics due to recent insider stock disposals. It is important for investors to consider insider selling activity as a data point, although it doesn't always predict future stock performance.
Protagonist Therapeutics stock gets USD 300.0 million buyback approval
Protagonist Therapeutics has received authorization for a $300.0 million share repurchase program, backed by its strong cash position and anticipated future payments. This comes after a significant increase in Q2 revenue to $213.47 million and diluted EPS of $2.29, with analyst BMO Capital Markets raising its price target to $190.00. The company's market capitalization stands at $9.0 billion.
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
Protagonist Therapeutics (NASDAQ: PTGX) has significantly outperformed the market over the last decade, with an average annual return of 20.58%. An initial investment of $100 in PTGX 10 years ago would now be valued at $668.69. This article highlights the substantial impact of compounded returns on investment growth over time.
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics announced the submission of an application to the European Medicines Agency (EMA) by Johnson & Johnson for icotrokinra, an investigational oral peptide for moderate-to-severe plaque psoriasis in adults and adolescents. The submission is based on four Phase 3 studies that met all primary and co-primary endpoints, demonstrating significant skin clearance and a favorable safety profile. Icotrokinra is designed to selectively block the IL-23 receptor and has shown superiority against deucravacitinib in trials.
The Peptide Boom That Isn’t About Your Muscles
The article discusses the growing interest in peptides, particularly focusing on Protagonist Therapeutics, a biotech company that has developed a way to deliver fragile peptides as powerful pills rather than injections. This innovation is highlighted as a significant development for biotech investors, moving beyond the current trend of injectable peptides used by biohackers and wellness consumers.
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?
Protagonist Therapeutics (NASDAQ:PTGX) shares gapped up before trading, opening at $141.81. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $147.13, and recently exceeded quarterly expectations with significant year-over-year revenue growth. Despite strong institutional ownership, insiders have sold a substantial amount of stock in the last quarter.
Protagonist Therapeutics (PTGX) Short Interest & Short Float | Updated Sep 2026
Protagonist Therapeutics (PTGX) reported an increase in short interest, with 8.14 million shares sold short as of September 15, 2026, representing 13.27% of its public float. This marks a 5.54% rise from the previous report, and the short interest ratio (days to cover) stands at 15.1 days, indicating a notable level of pessimistic sentiment among investors. The article details historical short interest data for PTGX and compares its short interest percentage to competitors in the biotechnology sector.
Protagonist Therapeutics, Inc. (PTGX) Stock forecasts
Argus has raised its target price for Protagonist Therapeutics Inc. (PTGX) to $152.00, noting the company's proprietary technology platform for developing novel peptide-based drug candidates. PTGX is a clinical-stage biopharmaceutical company, and its current stock price is $137.34. The report was published on September 23, 2026.
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 20% Potential Upside with Robust Revenue Growth
Protagonist Therapeutics (PTGX) shows a promising investment opportunity with a market cap of $9.38 billion and an impressive 3,749.20% revenue growth. Analysts project a potential upside of 20.49%, driven by its innovative pipeline for treatments like Icotyde and Rusfertide, despite the current lack of traditional valuation metrics. The company boasts strong analyst support with 13 buy ratings and a robust financial position evidenced by $96.15 million in free cash flow.
1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE
Bank of America Corp DE has acquired a new stake of 1,324,498 shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), valued at approximately $162.4 million, representing a 2.05% ownership. This purchase contributes to the 98.63% institutional ownership of the company. Analysts maintain a "Moderate Buy" rating for PTGX with a consensus price target of $147.13, following the company's strong Q2 earnings that exceeded revenue estimates significantly.
California State Teachers Retirement System Raises Position in Protagonist Therapeutics, Inc. $PTGX
The California State Teachers Retirement System significantly increased its stake in Protagonist Therapeutics, Inc. by 12,217.3% in the second quarter of 2026, now owning 11.17% of the company's stock valued at $885.9 million. This move is part of broader institutional interest, with other major investors like BlackRock and Johnson & Johnson also holding substantial positions. Protagonist Therapeutics reported strong quarterly results, with revenue up 3,746.8% year over year and earnings exceeding analyst estimates, contributing to a "Moderate Buy" consensus rating from analysts.
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX
Virginia Retirement Systems acquired 11,200 shares of Protagonist Therapeutics (NASDAQ:PTGX) for approximately $1.37 million, with institutional investors and hedge funds now owning 98.63% of the company. Analysts maintain a "Moderate Buy" rating with an average price target of $147.13, following strong Q2 earnings where the company surpassed revenue and EPS expectations. Despite positive analyst sentiment and revenue growth, company insiders have sold a significant amount of shares over the past 90 days.
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $1,048,759.80 in Stock
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph. Patel sold 7,278 shares for approximately $1.05 million, reducing his stake by 1.37%. This transaction, conducted under a Rule 10b5-1 plan, leaves him with 522,968 shares. The company recently reported strong Q2 earnings, beating analyst expectations with $2.29 EPS and significant revenue growth of 3,746.8% year-over-year.
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX
HSBC Holdings PLC significantly increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 1,260.9% in the second quarter, adding 24,045 shares and bringing its total holdings to 25,952 shares valued at approximately $3.2 million. This move comes as institutional investors collectively own 98.63% of the company, and despite recent insider selling of 234,000 shares worth $34.2 million. Analysts maintain a favorable outlook with a "Moderate Buy" rating and an average target price of $147.13, following strong Q2 earnings that surpassed estimates.
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com
Protagonist Therapeutics (PTGX) presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, highlighting its transition into a new phase with two recently approved drugs, a cash-rich balance sheet exceeding $1 billion, and a robust pipeline. The company discussed the successful launch of icotrokinra and the recent FDA approval of MIMRYLO/rusfertide, outlining plans for a $300 million share buyback while prioritizing research and development. Protagonist also detailed its advanced pipeline, including oral programs for inflammation, rare diseases, and obesity, emphasizing its peptide platform's validation and future growth strategy.
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10
Protagonist Therapeutics, Inc. presented at Citigroup's Biopharma Back to School Summit 2026 on September 9, 2026, at 10:40 AM. The transcript of this presentation features analyst Geoffrey Meacham and is available to subscribers. The article also provides a summary of recent news regarding Protagonist Therapeutics, including FDA approval for Mimrylo, updated analyst price targets, and insider transactions.
Protagonist Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript
This transcript details Protagonist Therapeutics, Inc.'s participation in the Citi Biopharma Back to School Summit held on September 9, 2026. CEO Dinesh Patel discusses the company's activities with Senior Biopharma Analyst Jess Meacham. The article also provides key financial data for Protagonist Therapeutics (NAS:PTGX), including market cap, enterprise value, and various ratios.
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
Protagonist Therapeutics has announced that its Board of Directors has authorized a share repurchase program of up to $300 million of its outstanding common stock. The company plans to fund these repurchases using its existing cash, cash equivalents, marketable securities, and future royalty and payment streams from its collaboration agreements with Takeda and Johnson & Johnson. This move aims to enhance shareholder value and demonstrates confidence in the company's financial position and future prospects.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Protagonist Therapeutics (NASDAQ:PTGX) has received a "Moderate Buy" consensus rating from eighteen brokerages, with an average 12-month price target of $147.13. The company recently reported strong quarterly earnings, beating analyst estimates with $2.29 EPS and revenue up 3,746.8% year-over-year. Institutional ownership is high at 98.63%, though insiders have sold approximately $16.9 million in stock over the past 90 days.
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Protagonist Therapeutics (NASDAQ:PTGX) announced that its CEO, Dinesh V. Patel, Ph.D., will participate in two investment bank conferences in September 2026: the Citi Biopharma Back to School Conference and the Cantor Global Healthcare Conference. The company will discuss its biopharmaceutical developments, including its FDA-approved medicines ICOTYDE™ and MIMRYLO™, and its pipeline drug candidates. Webcasts of the fireside chats will be available on the company's investor relations webpage.
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call
Protagonist Therapeutics (PTGX) has garnered investor attention following a recent update call, despite its shares already experiencing significant gains. While the stock's P/E ratio of 115.3x suggests it's overvalued compared to its fair P/E of 31.4x, Simply Wall St's discounted cash flow (DCF) model indicates the stock could be trading 63.3% below its estimated future cash flow value, suggesting it is undervalued. This presents mixed signals for investors, highlighting the need to weigh both earnings-based and cash flow-based valuations.
Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform
Wolfe Research has reiterated its Outperform rating for Protagonist Therapeutics (NASDAQ:PTGX) stock, setting an unchanged price target of $225.00. The firm projects peak sales of $2.9 billion by 2036, exceeding the consensus estimate, largely driven by the impressive clinical results of rusfertide. The stock has seen significant analyst optimism following strong Q2 2026 financial results and promising drug developments.
132,351 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Legal & General Group Plc
Legal & General Group Plc has acquired 132,351 shares of Protagonist Therapeutics, Inc. ($PTGX), valued at approximately $16.2 million, giving it a 0.20% stake in the company. Institutional investors now own 98.63% of PTGX, and analysts generally maintain a "Moderate Buy" rating with an average price target of $140.53. The company recently reported strong quarterly earnings, with EPS slightly above expectations and revenue up 3,746.8% year-over-year.
Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says
Wedbush anticipates that Protagonist Therapeutics' future growth will primarily be driven by its wholly-owned development programs rather than its partnerships. This assessment highlights the importance of the company's internal pipeline for its long-term success. The article is a brief statement from MT Newswires regarding Wedbush's outlook on PTGX.
Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept
Citigroup has increased its price target for Protagonist Therapeutics (PTGX) to $182 from $175, while maintaining a Buy rating on the stock. This adjustment reflects continued analyst confidence in the biopharmaceutical company. The report was published on August 31, 2026, at 02:41 pm EDT.
Hsbc Holdings PLC Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX
HSBC Holdings PLC recently acquired 25,952 shares of Protagonist Therapeutics (PTGX) valued at approximately $3.2 million, as institutional ownership of the company stands at 98.63%. Despite significant insider selling of 118,000 shares worth $16.9 million, analysts maintain a "Moderate Buy" rating with an average price target of $140.53, with several firms raising their targets. Protagonist Therapeutics also reported strong quarterly earnings of $2.29 per share and revenue of $213.47 million, marking a 3,746.8% year-over-year increase.
Wellington Management Group LLP Sells 182,863 Shares of Protagonist Therapeutics, Inc. $PTGX
Wellington Management Group LLP decreased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 5.1% in the second quarter, selling 182,863 shares but still holding over 3.4 million shares. Despite this sale, institutional investors and hedge funds collectively own 98.63% of the company. Protagonist Therapeutics reported strong quarterly earnings, exceeding analyst estimates, and its stock has seen a significant year-over-year revenue increase, with analysts maintaining a "Moderate Buy" rating.
The Manufacturers Life Insurance Company Purchases Shares of 108,555 Protagonist Therapeutics, Inc. $PTGX
The Manufacturers Life Insurance Company has acquired 108,555 shares of Protagonist Therapeutics (NASDAQ:PTGX) worth approximately $13.3 million. This purchase is part of broader institutional interest, with such investors collectively owning 98.63% of the company. Despite positive analyst sentiment and strong quarterly revenue growth of 3,746.8%, insiders have sold a significant amount of stock recently.
58,059 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Twin Lakes Capital Management LLC
Twin Lakes Capital Management LLC has acquired 58,059 shares of Protagonist Therapeutics (NASDAQ:PTGX), valued at approximately $7.1 million, making it 2.7% of their portfolio. This acquisition contributes to the 98.63% institutional ownership of the company. Despite insider sales totaling around 118,000 shares in the last three months, Protagonist Therapeutics reported strong quarterly earnings, surpassing analyst expectations with significant revenue growth.
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
Protagonist Therapeutics announced FDA approval for MIMRYLO (rusfertide), a first-in-class hepcidin mimetic peptide for adults with polycythemia vera. This approval triggers $275 million in payments to Protagonist, with potential for up to an additional $875 million in future milestones and tiered royalties. MIMRYLO offers a novel mechanism to control hematocrit levels, reduce phlebotomy burden, and improve fatigue, marking a significant advancement in the treatment of PV.
Bamco Inc. NY Makes New $1.96 Million Investment in Protagonist Therapeutics, Inc. $PTGX
Bamco Inc. NY has made a new $1.96 million investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by purchasing 16,000 shares. This move comes as institutional investors collectively own 98.63% of the company, despite recent insider share sales totaling $16.9 million. Analysts maintain a "Moderate Buy" rating with an average price target of $140.53, following the company's strong quarterly earnings and revenue report.
9,414 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by J. Goldman & Co LP
J. Goldman & Co LP recently acquired 9,414 shares of Protagonist Therapeutics (PTGX) valued at approximately $1.15 million during the second quarter. This move is part of broader institutional interest, with hedge funds and institutional investors owning 98.63% of the company's stock. Protagonist Therapeutics reported strong quarterly results, exceeding revenue and EPS estimates, despite some insider selling activity.
EFG International AG Buys Shares of 40,501 Protagonist Therapeutics, Inc. $PTGX
EFG International AG has acquired a new position in Protagonist Therapeutics (NASDAQ:PTGX), purchasing 40,501 shares valued at approximately $4.96 million during the second quarter. Other institutional investors like BlackRock Inc., Johnson & Johnson, Janus Henderson Group PLC, Wellington Management Group LLP, and Vanguard Group Inc. have also significantly modified their holdings in the company. Protagonist Therapeutics' stock performance, strong quarterly earnings, and "Moderate Buy" consensus rating from analysts indicate positive sentiment, though insider selling by CEO Dinesh V. Ph D. Patel and Director William D. Waddill was noted.
Elmind Capital LP Invests $4.66 Billion in Protagonist Therapeutics, Inc. $PTGX
Elmind Capital LP has acquired a new stake of 38,000 shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), valued at approximately $4.66 billion, making it their 21st largest holding. Other institutional investors have also adjusted their positions in PTGX, while company insiders have sold a significant number of shares recently. Analysts maintain a "Moderate Buy" consensus rating for Protagonist Therapeutics, with several firms raising their price targets.
Castleark Management LLC Buys Shares of 50,570 Protagonist Therapeutics, Inc. $PTGX
Castleark Management LLC has acquired 50,570 shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the second quarter, valued at approximately $6.2 million. This move makes Castleark Management LLC own about 0.08% of the company. Other institutional investors have also made changes to their positions in PTGX, while company insiders have sold a significant number of shares recently.
Protagonist Therapeutics, Inc. $PTGX Shares Bought by Algert Global LLC
Algert Global LLC increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 11.8% during the second quarter, owning 87,698 shares valued at $10.75 million. Other institutional investors like BlackRock Inc., Johnson & Johnson, Janus Henderson Group PLC, Wellington Management Group LLP, and Vanguard Group Inc. also made significant changes to their holdings. The article also details recent analyst upgrades, insider stock sales by Director William D. Waddill and CEO Dinesh V. Ph D. Patel, and the company's recent financial performance, including its Q2 earnings beat.
ADAR1 Capital Management LLC Makes New $117.78 Million Investment in Protagonist Therapeutics, Inc. $PTGX
ADAR1 Capital Management LLC has made a new significant investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), acquiring 960,863 shares valued at approximately $117.78 million, making it their second-largest position. Other institutional investors and hedge funds, including Johnson & Johnson and NEXTBio Capital Management LP, have also recently adjusted their stakes in the company. Protagonist Therapeutics has received a "Moderate Buy" average rating from analysts, with a price target of $140.53, and has shown strong financial performance with a significant revenue increase and insiders recently selling shares.
Northwestern Mutual Wealth Management Co. Purchases New Shares in Protagonist Therapeutics, Inc. $PTGX
Northwestern Mutual Wealth Management Co. has acquired 48,894 new shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) for approximately $5.99 million. This purchase is part of a broader trend of institutional investment in PTGX, with such entities owning 98.63% of the company. The company recently reported strong quarterly earnings, exceeding analyst expectations, and its stock is trading near its 52-week high, despite some insider selling activity.
Deutsche Bank AG Invests $17.39 Million in Protagonist Therapeutics, Inc. $PTGX
Deutsche Bank AG has acquired a new stake of 141,838 shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), valued at approximately $17.39 million, making them own about 0.22% of the company. Other institutional investors also adjusted their holdings, with institutional ownership reaching 98.63%. The article also details recent stock performance, earnings, analyst ratings, and insider trading activities for Protagonist Therapeutics.
BlackRock Inc. Makes New Investment in Protagonist Therapeutics, Inc. $PTGX
BlackRock Inc. has acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the second quarter, purchasing over 10.3 million shares valued at approximately $1.26 billion, now owning about 16.03% of the company. Other institutional investors have also adjusted their holdings, and Wall Street analysts have issued mostly "Buy" or "Strong Buy" ratings for PTGX. Insider activity shows recent sales by the CEO and a Director, while the company reported strong Q2 earnings, exceeding analyst expectations for both EPS and revenue.
Great Lakes Advisors LLC Invests $6.97 Million in Protagonist Therapeutics, Inc. $PTGX
Great Lakes Advisors LLC has acquired a new stake in Protagonist Therapeutics, Inc., purchasing 56,904 shares valued at approximately $6.98 million. This investment comes amidst significant institutional ownership of PTGX (98.63%) and generally favorable analyst sentiment, despite a recent downgrade by Zacks Research. Protagonist Therapeutics reported strong quarterly earnings with revenue up 3,746.8% year-over-year, though the stock has seen insider selling totaling $17.8 million in the last 90 days.
248,322 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Eagle Health Investments LP
Eagle Health Investments LP has acquired 248,322 shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) for approximately $30.44 million, making it their 8th largest position. Other institutional investors like BlackRock Inc. and Vanguard Group Inc. have also adjusted their holdings in PTGX. The article also notes recent insider selling by the CEO and a director, alongside several analyst upgrades and price target increases for Protagonist Therapeutics.
